Company Research Report: Cambridge Raman Imaging Ltd. (CRI)

Company Overview

• Name: Cambridge Raman Imaging Ltd. (CRI)

• Mission of the Company: CRI aims to offer highly precise and detailed imaging of tissues and cells, striving for more accurate diagnoses of diseases and a better understanding of their underlying mechanisms. The company leverages pioneering laser technology, computational imaging, and AI to deliver rapid, high-resolution images for biomedical solutions.

• Founded: March 2018

• Founders: Giulio Cerullo and Andrea Ferrari

• Key People:

• Matteo Negro: CEO & Co-founder

• Francesco Crisafi: CTO

• Elisa Pinelli: Quality Assurance & Regulatory Manager

• Francesca Marinoni: Production & Supply Chain Manager

• Board members include Neil Crabb (Chairman) and Paul Mantle (Director).

• Scientific Advisors: Andrea Ferrari, Giulio Cerullo

• Headquarters: Botanic House, 100 Hills Road, Cambridge, Cambridgeshire, CB2 1PH, UK

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: CRI is recognized for using coherent Raman scattering microscopy to create high-speed, truly label-free imaging, enabling scanning of tumor tissue in seconds.

Products

STRALE

• Description: A designed Raman laser system to fully exploit broadband stimulated Raman scattering (SRS) without compromises.

• Key Features:

• Plug-and-play SRS post-installation

• Wide spectral coverage ranging from 2800 cm⁻¹ to 3100 cm⁻¹ in a single shot with high spectral resolution.

• Dual-output pulse duration for non-linear optical microscopy techniques.

• Compact and stable due to all-fiber architecture.

• Essential for fast, non-destructive experiments on live biological samples.

CHAMP

• Description: An advanced optical spectrometer that can be sold as an add-on or standalone system.

• Key Features:

• Designed for comprehensive platforms integrated into existing microscopy structures.

• Supports fast data scale-up and transfer processes.

• Provides synergistic design with laser source for real-time full-chemical imaging.

Recent Developments

• Recent Projects:

• MINDSET Project: Focuses on virtual histopathology, fundamentally transforming cancer diagnosis.

• CHARM Project: Developing a medical device using high-speed, low-cost Raman imaging technology coupled with AI to enable faster and label-free cancer diagnosis.

• CRIMSON Project: A consortium initiative for monitoring diseases at a molecular level, funded by the European Commission.

• Funding:

• Raised £1.1 million through an equity funding round, valued at £6.1 million post-round, indicating robust investor confidence.

• Received €3.3 million grant from the European Innovation Council for the CHARM project.

• Partnerships & Collaborations:

• Collaboration with Motic for the development of Raman imaging microscope prototypes.

• European partnerships in EU-funded projects for advancing medical diagnostics and treatment solutions.

• Recognition:

• Featured in the European HealthTech Market Map 2022 by AlbionVC for its work in digital biomarkers, imaging, diagnostic, and clinical decision support.

In conclusion, Cambridge Raman Imaging Ltd. continues to make significant strides in the field of biomedical imaging, leveraging its advanced technologies and growing network to transform disease diagnosis and treatment.